DIMERIX SUCCESSFULLY PASSES EFFICACY INTERIM ANALYSIS IN ACTION3 PHASE 3 STUDY FOR FSGS KIDNEY DISEASE
Posted: 12 March 2024 Dimerix Limited (ASX: DXB, “Dimerix”), today announced that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) was successful in the pre-specified interim analysis of the proteinuria (efficacy) endpoint…
Avecho receives Ethics Approval for amendments to Phase III Insomnia Clinical Trial
Posted: 12 March 2024 Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), a biotechnology company focused on developing and commercialising innovative products using its proprietary Tocopheryl Phosphate Mixture (“TPM®”) drug delivery system, is pleased to announce it…
La Trobe and Healthscope invest in health skills
Posted: 12 March 2024 Furthering La Trobe University’s commitment to world-class health innovation and excellence in education, La Trobe Private Hospital provides students and researchers with enhanced opportunities to develop job-ready clinical skills, while offering better health outcomes…
Cynata’s drug reduces wound surface area in diabetic foot ulcers
Posted: 12 March 2024 Cynata Therapeutics (ASX:CYP) has also updated the market on the progress of its diabetic foot ulcers clinical trial. Cynata said it has completed its initial analysis of wound surface area in the first 16 patients…
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Posted: 12 March 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first ever 90mg…
New Myalgic Encephalomyelitis research funding
Posted: 12 March 2024 The funding from the Mason Foundation, announced today, will help find solutions to ME, also referred to as chronic fatigue syndrome. Two of La Trobe University’s projects were selected for funding from the foundation’s…
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
Posted: 12 March 2024 Telix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for…
2023 Member Survey results
Posted: 6 March 2024 On 8 December 2023, BioMelbourne Network invited our members to complete the 2023 Member Survey which closed on 31 January 2024. We conduct this survey annually and track the trends year on year, so…
Potential to use Deoxymabs to treat autoimmune diseases
Posted: 5 March 2024 Patrys has announced that new data from preclinical studies using PAT-DX1 in animal models of anti neutrophil cytoplasmic antibody (ANCA) vasculitis will be presented at the 21st International Vasculitis Workshop in Barcelona next month. Dr Kim O’Sullivan…
Florey researchers paving way forward for MS treatments
Posted: 5 March 2024 Florey researchers Associate Professor Justin Rubio and Dr Sarrabeth Stone have been awarded a combined total of $900,000 to propel research looking into treatments for multiple sclerosis. Associate Professor Justin Rubio has been awarded $650,000…
Jobs Boost As World-Leading Company Makes Parkville Home
Posted: 5 March 2024 The Allan Labor Government is ensuring Parkville continues to grow as a world-leading biomedical precinct, attracting global investment and creating local jobs as more companies choose to make it their home. Minister for Precincts…
Monash University and Moderna Regional Research Centre appoint industry expert to lead mRNA medicine joint-venture
Posted: 5 March 2024 Monash University and Moderna have together appointed Professor Noelia Nebot as the inaugural Director of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA), which was launched in 2023 to drive advancements in homegrown mRNA medicines. Professor Nebot will…
